 Connection
William Robinson to Neoplasms, Second Primary
This is a "connection" page, showing publications William Robinson has written about Neoplasms, Second Primary.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.481 |
|
|
|
-
Vaddi PK, Osborne DG, Nicklawsky A, Williams NK, Menon DR, Smith D, Mayer J, Reid A, Domenico J, Nguyen GH, Robinson WA, Ziman M, Gao D, Zhai Z, Fujita M. CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients. Front Immunol. 2023; 14:1173035.
Score: 0.195
-
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
Score: 0.193
-
Ellis LZ, Prado R, High W, Robinson WA, Mellette JR. Sweat gland carcinoma versus metastatic breast carcinoma: a continued struggle among clinicians and dermatopathologists. J Am Acad Dermatol. 2012 Oct; 67(4):e156-7.
Score: 0.093
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|